#Pharmaceuticals

🏢Release 📈 Stocks

Eli Lilly Omvoh Hits Pediatric Ulcerative Colitis Primary Endpoint

October 19, 2026 (3 minutes ago)

Eli Lilly eyes label expansion for Omvoh after pediatric ulcerative colitis trial data shows 80% induction response rate, strengthening the drug's clinical…

LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks — 📊 Neutral

Global ADHD Drug Market Projected to Reach USD 28.5 Billion by 2035

October 16, 2026 (2 days ago)

Valued at USD 14.11 billion in 2025, the global ADHD drug market is forecast to experience robust growth through 2035, fueled by…

🌍 GLOBAL Read More →

🏢Release 📈 Stocks — 📊 Neutral

Antihypertensive Drug Market Projected to Reach Significant Growth by 2035

October 16, 2026 (2 days ago)

Credence Research reports steady growth for the global antihypertensive drugs market, citing increased demand for blood pressure management solutions as the primary…

🌍 GLOBAL Read More →

🏢Release 📈 Stocks — 📊 Neutral

Global Antiviral Drugs Market Projected to Reach Significant Growth by 2035

October 15, 2026 (3 days ago)

Valued at USD 77.93 billion in 2025, the global antiviral drugs market enters a decade of projected growth driven by pharmaceutical innovation…

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Eli Lilly Sets October 29 Date for Third-Quarter 2026 Financial Results

October 15, 2026 (3 days ago)

Eli Lilly confirms it will report Q3 2026 financial results on October 29, 2026, followed by a scheduled conference call with the…

LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks — 📊 Neutral

SCRS Launches Intelligence Platform to Accelerate Clinical Site Engagement

October 15, 2026 (3 days ago)

SCRS introduces a new intelligence platform to help pharmaceutical sponsors and CROs identify operational gaps and improve clinical site engagement efficiency.

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Opella Study Links Cough Treatment Efficacy to Patient Well-Being Metrics

October 15, 2026 (4 days ago)

Opella's latest real-world study highlights the importance of patient well-being metrics in evaluating cough treatments, signaling a potential shift in clinical standards…

OPL

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Novo Nordisk and Eli Lilly Face Rising GLP-1 Litigation Risks Over NAION

October 14, 2026 (4 days ago)

Federal litigation involving GLP-1 medications and NAION diagnoses expands, creating potential mid-term liability risks for industry leaders Novo Nordisk and Eli Lilly.

NVO LLY

🌍 US Read More →

🏢Release 📈 Stocks

Johnson & Johnson TREMFYA Hits 94% Remission Rate in Crohn's Disease Study

October 12, 2026 (6 days ago)

Johnson & Johnson's TREMFYA demonstrates strong efficacy in Crohn's disease trials, with 94% clinical remission and 61% endoscopic remission, bolstering the company's…

JNJ

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Johnson & Johnson Shares Gain as TREMFYA Shows Crohn's Disease Efficacy

October 12, 2026 (6 days ago)

Johnson & Johnson's TREMFYA shows consistent perianal fistula remission in Crohn's disease patients, bolstering the company's pharmaceutical outlook.

JNJ

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Zydus Lifesciences Reports 60.7% PBC Treatment Response in U.S. Subgroup

October 12, 2026 (6 days ago)

Zydus Lifesciences shares gain momentum as Phase 3 EPICS-III trial data reveals superior biochemical response rates for saroglitazar in U.S. patients suffering…

ZYDUSLIFE

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

GSK Partners With Viola Davis to Boost Shingles Awareness Among Adults 50+

October 8, 2026 (10 days ago)

GSK taps Viola Davis for a national shingles awareness campaign targeting adults over 50, focusing on the health risks associated with aging…

GSK

🌍 AMERICAS Read More →